CSPC Pharma (01093): CSPC Innovation (300765.SZ) recorded a net profit attributable to equity holders of approximately 0.139 billion yuan in the first three quarters, a decrease of 63.5% year-on-year.

CSPC Pharma (01093) announced the performance of CSPC Innovation (300765.SZ) in the third quarter of 2024...

Wise Finance APP News, CSPC Pharma (01093) announced the performance of CSPC Innovation (300765.SZ) in the third quarter of 2024, with revenue of approximately 0.507 billion yuan, a 14.48% decrease year-on-year; net income attributable to the shareholders of the listed company is approximately 2.3019 million yuan, a 98.03% decrease year-on-year; basic earnings per share is 0.002 yuan.

From January to September, revenue was approximately 1.479 billion yuan, a 23.66% decrease year-on-year; net income attributable to the shareholders of the listed company is approximately 0.139 billion yuan, a 63.5% decrease year-on-year; basic earnings per share is 0.0995 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

石药集团(01093)：石药创新(300765.SZ)前三季度归母净利约1.39亿元 同比减少63.5%

CSPC Pharma (01093): CSPC Innovation (300765.SZ) recorded a net profit attributable to equity holders of approximately 0.139 billion yuan in the first three quarters, a decrease of 63.5% year-on-year.

Risk Disclaimer

Statement

石药集团(01093)：石药创新(300765.SZ)前三季度归母净利约1.39亿元同比减少63.5%